Probenecid

• Description :

  Probenecid is a potent and selective agonist of transient receptor potential vanilloid 2 (TRPV2) channels. Probenecid also inhibits pannexin 1 channels.

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Bacterial; HIV; TRP Channel

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Probenecid.html

• Concentration :

  10mM

• Purity :

  99.92

• Solubility :

  0.5 M NaOH : 100 mg/mL (ultrasonic; adjust pH to 12 with NaOH) |DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(O)C1=CC=C(S(=O)(N(CCC)CCC)=O)C=C1

• Molecular Formula :

  C13H19NO4S

• Molecular Weight :

  285.36

• Precautions :

  H302

• References & Citations :

  [1]Koch SE, et al. Probenecid: novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation. J Mol Cell Cardiol. 2012 Jul;53 (1) :134-44.|[2]Bakos E, et al. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000 Apr;57 (4) :760-8.|[3]Greene TA, et al. Probenecid inhibits the human bitter taste receptor TAS2R16 and suppresses bitter perception of salicin. PLoS One. 2011;6 (5) :e20123.|[4]Silverman W, et al. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol. 2008 Sep;295 (3) :C761-7.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  TRPV2

• Citation 01 :

  ACS Environ Au. 2025 Aug 8.|Acta Pharmacol Sin. 2025 Sep 15.|Adv Sci (Weinh) . 2025 May 8:e2503579.|Adv Sci (Weinh) . 2025 Oct 6:e10270.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|Biochem Biophys Res Commun. 2024 May 15:721:150128.|Biopharm Drug Dispos. 2022 Dec;43 (6) :265-271.|Cell Calcium. 2024 Apr 8, 102883.|Cell Mol Immunol. 2020 Mar;17 (3) :261-271.|Cell Rep. 2025 Mar 25;44 (4) :115466.|Cell Res. 2022 Jul;32 (7) :638-658.|Chem Biol Interact. 2024 Oct 29:111293.|Drug Deliv. 2025 Dec;32 (1) :2490269.|Exp Neurol. 2025 Jan:383:115040.|Food Res Int. 2025 Feb:201:115590. |Front Pharmacol. 2022 Feb 23:13:816133.|Front Pharmacol. 2022 Feb 23;13:816133.|Immunity. 2022 Apr 12;55 (4) :686-700.e7.|Int J Biol Sci. 2022 Apr 11;18 (7) :2914-2931.|Int J Mol Sci. 2019 Mar 5;20 (5) . pii: E1125. |J Agric Food Chem. 2016 Oct 26;64 (42) :7899-7910. |J Dig Dis. 2025 Jan-Feb;26 (1-2) :62-73.|J Endocrinol Invest. 2025 Feb;48 (2) :317-332.|J Transl Med. 2025 Jul 11;23 (1) :781.|Lasers Surg Med. 2017 Sep;49 (7) :719-726.|Mol Pharmacol. 2025 Oct 27.|Neuroscience. 2022 Jul 1:494:51-68.|Regul Toxicol Pharmacol. 2019 Nov:108:104449.|Res Sq. 2024 Nov 17.|Research Square Preprint. 2021 Aug.|Research Square Print. August 31st, 2022.|Toxicol Appl Pharmacol. 2024 Nov:492:117112.|Toxicol In Vitro. 2020 Dec;69:104971.|Transl Res. 2024 May 9:271:26-39.|World J Tradit Chin Med. 2025 August 01.|J Vet Intern Med. 2025 Sep-Oct;39 (5) :e70221.

• CAS Number :

  [57-66-9]